Granted Patent B2

US 12,565,518 · App. 18/435,939 · Granted Mar 3, 2026

Inventors: Jun O. Liu (Clarksville, MD); Jingxin Wang (Baltimore, MD); Zufeng Guo (Baltimore, MD); Wei Li (Xiangtan, CN); Shridhar Bhat (Cockeysville, MD); Manisha Das (Centreville, MD)

Assignee: The Johns Hopkins University

C07K7/645A61K31/4353A61K31/436C07D471/04C07D498/04C07D498/14C07D515/04C07D515/14C07K17/08G01N33/566

Abstract

Claims (67)

1 . A method of treating a hyperproliferative disorder in a patient in need thereof comprising: administering a therapeutically effective amount of a compound of Formula I

or a pharmaceutically acceptable salt or solvate thereof, to the patient, thereby treating the disorder;

wherein:

is a single or double bond;

X 1 is O or NR 6 ;

Y is —C(O)—

X 2 is (CH 2 ) m , O, or NR 6 ;

Z is

W is O, CH, CH 2 , CR 4 , or CR 5 ;

L 1 and L 2 are each independently a direct bond, substituted or unsubstituted —(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n O(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)—, substituted or unsubstituted —(CH 2 ) n C(O)(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)O(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n NH(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)NH(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n S(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)(CH 2 ) n S(C 1 -C 6 )alkyl-, substituted or unsubstituted —(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n O(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)O(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n NH(C 1 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)NH(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n S(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)(CH 2 ) n S(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n O(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)O(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n NH(C 1 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)NH(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n S(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)(CH 2 ) n S(C 2 -C 6 )alkynyl-, wherein each alkyl, alkenyl and alkynyl group may be optionally substituted with alkyl, alkoxy, amino, carboxyl, cyano, nitro, or trifluoromethyl;

each m is independently an integer selected from 0, 1, 2, 3, 4, 5, and 6;

each n is independently an integer selected from 0, 1, 2, 3, 4, 5, and 6;

R 1 is hydrogen, hydroxyl, or OPG, wherein PG is a protecting group, or

R 1

 wherein

 is a resin;

R 2 is hydrogen, hydroxyl, or alkoxy;

R 3 is hydrogen or alkyl;

R 4 and R 5 are each independently hydrogen, hydroxy, alkyl, alkoxy, or OPG, wherein PG is a protecting group;

R 6 is hydrogen or alkyl;

wherein the Effector Domain has Formula II:

wherein:

R 7 , R 9 , R 11 , R 13 , and R 15 are each independently hydrogen or alkyl;

R 8 , R 10 , R 12 , and R 14 are each independently hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted perfluoroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkylaryl, (CH 2 ) n CN, (CH 2 ) n CF 3 , (CH 2 ) n C 2 F 5 , (CH 2 ) n OR 16 , (CH 2 ) n C(O)R 16 , (CH 2 ) n C(O)OR 16 , (CH 2 ) n OC(O)R 16 , (CH 2 ) n NR 17 R 18 , (CH 2 ) n C(O)NR 17 R 18 , (CH 2 ) n N 19 RC(O)R 16 , (CH 2 ) n N 19 RC(O) OR 16 , (CH 2 ) n NR 19 C(O)NR 17 R 18 , (CH 2 ) n SR 16 , (CH 2 ) n S(O) j NR 17 R 18 , (CH 2 ) n N 19 RS(O) j R 16 , or —(CH 2 ) n NR 19 S(O) j NR 17 R 18 ,

n is an integer selected from 0, 1, 2, 3, 4, 5, and 6;

j is an integer selected from 0, 1, and 2;

R 16 , R 17 , R 18 , and R 19 are each independently hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, or heteroalkylaryl, or

R 16 and R 19 are as described above, and R 17 and R 18 , together with the N atom to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered heterocycloalkyl or a substituted or unsubstituted 5-membered heteroaryl,

wherein each of the above groups listed for R 8 , R 10 , R 12 , and R 14 may be optionally independently substituted with 1 to 3 groups selected from halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, heteroalkylaryl, (CH 2 ) n CN, (CH 2 ) n CF 3 , (CH 2 ) n C 2 F 5 , (CH 2 ),OR 16 , (CH 2 ) n C(O)R 16 , (CH 2 ) n C(O) OR 16 , (CH 2 ) n OC(O)R 16 , (CH 2 ) n NR 17 R 18 , (CH 2 ) n C(O)NR 17 R 18 , (CH 2 ) n N 19 RC(O)R 16 , (CH 2 ) n N 19 RC(O) OR 16 , (CH 2 ) n NR 16 C(O)NR 17 R 18 , (CH 2 ) n SR 16 , (CH 2 ) n S(O) j NR 17 R 18 , (CH 2 ) n N 19 RS(O) j R 16 , and —(CH 2 ) n NR 19 S(O) j NR 17 R 18 .

2 . The method of claim 1 , wherein:

X is O or NR 6 ;

L 1 and L 2 are each independently —(C 1 -C 6 )alkyl-, —(CH 2 ) n O(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)(C 1 -C 6 )alkyl-, —(CH 2 ),C(O)O(C 1 -C 6 )alkyl-, —(CH 2 ) n NH(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)NH(C 1 -C 6 )alkyl-, —(CH 2 ) n S(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)(CH 2 ) n S(C 1 -C 6 )alkyl-, —(C 2 -C 6 )alkenyl-, —(CH 2 ) n O(C 2 -C 6 )alkenyl-, —(CH 2 ) n C(O)(C 2 -C 6 )alkenyl-, —(CH 2 ) n C(O)O(C 2 -C 6 )alkenyl-, —(CH 2 ) n NH(C 1 -C 6 )alkenyl-, —(CH 2 ) n C(O)NH(C 2 -C 6 )alkenyl-, —(CH 2 ) n S(C 2 -C 6 )alkenyl-, —(CH 2 ),C(O)(CH 2 ) n S(C 2 -C 6 )alkenyl-, wherein each alkyl and alkenyl group may be substituted with alkyl, alkoxy, or carboxyl;

n is an integer selected from 0, 1, 2, 3, 4, 5, and 6;

R 1 is hydrogen, hydroxyl, or OPG, wherein PG is a silyl protecting group, or

R 1 is

wherein

 is a resin;

R 2 is hydroxyl or alkoxy;

R 3 is hydrogen or alkyl;

R 4 and R 5 are each independently hydrogen, alkyl, alkoxy, or OPG, wherein PG is a silyl protecting group;

R 6 is hydrogen;

R 7 , R 9 , R 11 , R 13 , and R 15 are each independently hydrogen or CH 3 ;

R 8 , R 10 , R 12 , and R 14 are each independently substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted cycloheptyl, or substituted or unsubstituted cyclooctyl; or

R 8 , R 10 , R 12 , and R 14 are each independently substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydrothiophenyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted 1,3-dioxolanyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted 1,4-dioxanyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, or substituted or unsubstituted 1,4-dithianyl; or

R 8 , R 10 , R 12 , and R 14 are each independently substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylenyl, or substituted or unsubstituted biphenyl; or

R 8 , R 10 , R 12 , and R 14 are each independently substituted or unsubstituted furanyl, substituted or unsubstituted thiophenyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyridizanyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted triazinyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted benzo(b)thiophenyl, substituted or unsubstituted indolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted indazolyl, substituted or unsubstituted benzisoxazolyl, substituted or unsubstituted benzoxazolyl, substituted or unsubstituted benzothiazolyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted isoquinolinyl, substituted or unsubstituted quinazolinyl, substituted or unsubstituted quinoxalinyl, or substituted or unsubstituted naphthyridinyl.

3 . The method of claim 1 , wherein:

L 1 and L 2 are each independently —(C 1 -C 6 )alkyl-, —(CH 2 ) n O(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)(C 1 -C 6 )alkyl-, —(CH 2 ) n NH(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)NH(C 1 -C 6 )alkyl-, —(C 2 -C 6 )alkenyl-, —(CH 2 ) n O(C 2 -C 6 )alkenyl-, —(CH 2 ) n C(O)(C 2 -C 6 )alkenyl-, —(CH 2 ) n NH(C 1 -C 6 )alkenyl-, —(CH 2 ) n C(O) NH(C 2 -C 6 )alkenyl-, wherein each alkyl and alkenyl group may be substituted with alkyl, alkoxy, or carboxyl;

n is an integer selected from 0, 1, 2, 3, 4, 5, and 6;

R 1 is hydrogen, hydroxyl or OPG, wherein PG is a tert-butyldimethylsilyl protecting group, or

R 1 is

 wherein

 is Wang resin;

R 4 and R 5 are each independently hydrogen, hydroxy, alkyl, alkoxy, or OPG, wherein PG is a tert-butyldimethylsilyl protecting group;

R 7 , R 9 , R 11 , R 13 , and R 15 are each independently hydrogen;

R 8 , R 10 , R 12 , and R 14 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted benzyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted indolyl, (CH 2 ) n OR 5 , (CH 2 ) n C(O)NR 6 R 7 , or (CH 2 ) n SR 5 ; and

R 16 , R 17 , and R 18 are each independently hydrogen or (C 1 -C 6 )alkyl.

4 . The method of claim 1 , wherein:

L 1 and L 2 are each independently —(C 1 -C 6 )alkyl-, —O(C 1 -C 6 )alkyl-, —C(O)(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)NH(C 1 -C 6 )alkyl-, —(C 2 -C 6 )alkenyl-, —O(C 2 -C 6 )alkenyl-, —C(O)(C 2 -C 6 )alkenyl-, —(CH 2 ) n C(O)NH(C 2 -C 6 )alkenyl-, wherein each alkyl and alkenyl group may be substituted with alkyl, alkoxy, or carboxyl;

n is an integer selected from 0, 1, 2, 3, 4, 5, and 6;

R 8 , R 10 , R 12 , and R 14 are each independently H, CH 3 , CH 2 OH, CH 2 SH, CH(OH)CH 3 , CH 2 C(O)NH 2 , CH 2 CH 2 C(O)NH 2 , CH 2 CH 2 SCH 3 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 C 6 C 5 ,

5 . The method of claim 1 , wherein:

L 1 and L 2 are each independently —OCH 2 CH 2 —, —CH 2 C(O)—, —CH 2 CH 2 C(O)—, —C(O)NHCH 2 CH 2 , —CH 2 CH═CHCH 2 —, —OCH 2 CH═CHCH 2 CH 2 —, —OCH 2 CH═CHCH 2 CH(CO 2 H)—, —CH 2 C(O)NHCH 2 CH 2 —, or CH 2 CH(OCH 3 )═C(CH 3 ) CH 2 CH 2 ; and

R 8 , R 10 , R 12 , and R 14 are each independently the sidechain of the amino acid alanine, asparagine, cysteine, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.

6 . The method of claim 1 , wherein the compound has Formulae II, III, IV, V, or VI:

7 . The method of claim 1 , wherein the compound has Formulae VII, VIII, IX, or X:

8 . The method of claim 1 wherein the hyperproliferative disorder is selected from melanoma, skin cancer, breast cancer, bladder cancer, colon cancer, glioma, glioblastoma, lung cancer, hepatocellular cancer, gastric cancer, melanoma, thyroid cancer, endometrial cancer, renal cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, ovarian cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic diseases, stroke, diabetes, hepatomegaly, cardiovascular disease, Alzheimer's disease, cystic fibrosis, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders, inflammation, neurological disorders, hormone-related diseases, conditions associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, hyperproliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), liver disease, pathologic immune conditions involving T cell activation, CNS disorders, or a combination thereof.

Assignments (1)

Continuity (7)

References Cited (10)